The medtech company offers a digital solution – the ObvioHealth app– that eases the challenges of conducting traditional clinical research
ORLANDO, Fla – JULY 18, 2018 – ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies - the ObvioHealth app. The app removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, lowering drop-out rates and accelerating data capture – all of which help reduce exorbitant costs for study sponsors and create opportunities to leverage the data capture from connected devices for clinical evaluation.
“For decades, the clinical research industry has followed an archaic model, but now there’s a better option,” said Bryan Silverman, CEO of ObvioHealth: “Our mobile model challenges the industry to put patients first. This app allows study subjects to take part in important healthcare research from the comfort of their homes.”
The app maintains best-in-class clinical standards and compliance in studies ranging from pharmaceutical and nutrition, to observational and more. ObvioHealth’s clinical professionals and medical doctors monitor each study while study participants use the app on their smart phones or tablets, recording study specific information and allowing for real-time data collection.
Study protocols can be designed with smart devices, such as a Bluetooth blood pressure monitor, and the data from such devices immediately integrates with the app – providing real-world evidence. The app also offers real-time, 24/7 data monitoring, meaning adverse events are detected immediately. Healthcare professionals can video chat or text with participants at any time.
ObvioHealth is financially backed by TKS1, a venture capital collaboration between SPRIM, a life sciences consulting agency with deep experience as a clinical research organization, and Tikehau Capital (TKO.FP), an alternative asset management and investment company. In March, ObvioHealth received a Series A investment.
“Our app will help advance the latest treatments in healthcare, which is why we invested so confidently in ObvioHealth,” said Bruno de Pampelonne, CEO of Tikehau IM. “We’re happy to see the technology come to fruition and believe its transformation of the industry is just getting started.”
Find more information on the app, visit ObvioHealth’s official site here.
ObvioHealth is a full-service CRO that uses technology to drive clinical research in a cost-effective manner. As a medical technology company, ObvioHealth provides healthcare clients a data-rich platform for substantiating claims and demonstrating product safety and efficacy.
ObvioHealth's proprietary application allows clinical trials to be conducted online. This decentralized model means clinical trials can be executed from a participant’s smart phone, while leveraging the best-practices in study design, data management and medical writing–all in a streamlined platform.
SPRIM is a global life sciences innovation firm. With a team of 600+ professionals and 19 offices globally, SPRIM helps its clients transform the newest opportunities and breakthroughs in science and health, into business and marketing realities. After 17 years in business, SPRIM offers its services to more than 450 customers around the globe. Further information can be found at www.sprim.com.
Tikehau Capital is an asset management and investment group with €14.2 billion (at March 31, 2018) worth of assets under management and equity of €2.5 billion (as at December 31, 2017). The Group invests in various classes of assets (i.e., private debt, real-estate, private equity and liquid strategies), particularly through its asset management subsidiary Tikehau IM, on behalf of both institutional and private investors. Tikehau Capital is controlled by its managers and leading institutional partners and employs 220 staff (as at March 31, 2018) in its Paris, London, Brussels, Madrid, Milan, New York, Seoul and Singapore offices.
Tikehau Capital is listed on Euronext Paris, compartment A (ISIN code: FR0013230612; Ticker: TKO.FP)